anti-PD-1 antibody · antibody
zimberelimab
1 active trials across 4 of our biomarkers, targeting PD-1. Not approved for any biomarker on marked.bio yet.
Also known as AB122.
Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.
Biomarkers
| Biomarker | Active trials | All trials | Furthest active phase |
|---|---|---|---|
| KRAS G12C | 1 | 1 | Phase 1 |
| KRAS G12D | 1 | 1 | Phase 1 |
| EGFR exon 19 deletion / L858R | 0 | 1 | – |
| MSI-H / dMMR | 0 | 1 | – |
Sponsors
Industry sponsors leading active biomarker-selected trials of zimberelimab.
- Taiho Pharmaceutical 1
Trials
1 of 3 trials shown
-
AB122 Platform Study
zimberelimabTAS-116futibatinibTAS-115trifluridine/tipiracilramucirumabbevacizumabfluorouracilcisplatinAB154carboplatinnab-paclitaxel
…ras) oncogene homolog (NRAS) (exon 2, 3 and 4) wild type. \[Mutant is defined as at least KRAS or NRAS mutant (any exon, any mutation)\].
KRAS G12CKRAS G12DAdvanced or Metastatic Solid Tumor, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Non-small Cell Lung Cancer
-
Zimberelimab Anti-PD1 +/- Domvanalimab in Resectable Mmrd Gastric Cancer
MMRd/MSI-H.
MSI-H / dMMRLocally Advanced Gastric Adenocarcinoma, MSI-H/dMMR Gastric Cancer, MSI-H/dMMR Gastroesophageal-junction Cancer
-
A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer
Etrumadenantzimberelimabcarboplatinpemetrexedpembrolizumab
Arm 1 and Arm 2 participants must have a sensitizing epidermal growth factor receptor (EGFR) mutation with disease progression or treatment intolerance after one or more approved TKIs.
EGFR exon 19 deletion / L858RNon Small Cell Lung Cancer Metastatic, Non Small Cell Lung Cancer, Nonsquamous Nonsmall Cell Neoplasm of Lung, Sensitizing EGFR Gene Mutation
No trials match these filters.